Charles Hanes, MD
Urogynecology and Reconstructive Pelvic Surgery · Mobile, ALNPI 1639117526
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,000 of the $27,520 with a category attached, or 76.3%. Applied Medical Resources Corporation accounts for 96.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $11,941 and has fallen 99.3% since, to $78 in 2025.
Across 76 payments — averaging $362.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Applied Medical Resources Corporation$27K
- AbbVie$255
- Boston Scientific$99
- Astellas Pharma US Inc$72
- Axonics, Inc.$72
- Coloplast$71
- plus $402 from 16 others
What the payments were for
- Speaking & faculty fees$21,00076%
- Travel & lodging$5,14419%
- Food & beverage$1,3765%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Applied Medical Resources Corporation | 30 | $26,550 |
| AbbVie(2 entities) | 13 | $255 |
| Boston Scientific | 3 | $99 |
| Astellas Pharma US Inc | 3 | $72 |
| Axonics, Inc. | 3 | $72 |
| Coloplast | 1 | $71 |
| Baxter Healthcare | 4 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Medtronic | 1 | $47 |
| Johnson & Johnson(2 entities) | 2 | $39 |
| Coopersurgical, Inc. | 2 | $30 |
| Laborie Medical Technologies Corp. | 1 | $25 |
| Shield Therapeutics Inc | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| BD | 1 | $15 |
| Millicent US Inc | 1 | $14 |
| Mission Pharmacal Company | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
| KARL Storz Endoscopy-america | 1 | $12 |
| Sage Therapeutics, LLC | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GelPOINT V-Path$26,122
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 121 | $70,262 |
| GemtesaVibegron | 66 | $41,223 |
| Methenamine Hippurate | 96 | $8,090 |
| Solifenacin Succinate | 25 | $649 |
| Oxybutynin Chloride ErOxybutynin Chloride | 37 | $626 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $239 |
| Tamsulosin Hcl | 16 | $96 |
| Levofloxacin | 22 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $72 | $70,262121 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $51 | $41,22366 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Mobile
- Vincent ScottMobile$10K
- Robert BrownMobile$8K
- Brent ParnellBirmingham$208K
- Himanshu AggarwalMontgomery$19K
- George FahyBay Minette$14K
- Alison PickeringHomewood$11K
- David EllingtonBirmingham$9K
- Nicole MassieHomewood$8K
- Meagan CramerHomewood$3K
- Gabriela HalderBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.